Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | SMO | Q99835 | 2/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23564389 | 1.00 | TSHR (0.54) | TSHRCYP3A4CYP2C19MAPTMEN1 | |
| SCHEMBL23564393 | 1.00 | TSHR (0.54) | TSHRCYP3A4CYP2C19MAPTMEN1 | |
| SCHEMBL23563775 | 1.00 | TSHR (0.54) | TSHRCYP3A4CYP2C19MAPTMEN1 | |
| SCHEMBL19290951 | 0.86 | TSHR (0.51) | TSHRCYP3A4CYP2C19MAPTMEN1 | |
| SCHEMBL23564308 | 0.84 | TSHR (0.50) | TSHRCYP3A4CYP2C19MAPTMEN1 | |
| SCHEMBL23527035 | 0.84 | TSHR (0.50) | TSHRCYP3A4CYP2C19MAPTMEN1 | |
| SCHEMBL23527120 | 0.84 | TSHR (0.50) | TSHRCYP3A4CYP2C19MAPTMEN1 | |
| SCHEMBL23564623 | 0.84 | TSHR (0.50) | TSHRCYP3A4CYP2C19MAPTMEN1 | |
| SCHEMBL17426060 | 0.82 | EHMT2 (0.51) | TSHRCYP3A4CYP2C19MAPTEHMT2 | |
| SCHEMBL3601108 | 0.80 | PTGDR2 (0.49) | TSHRCYP3A4CYP2C19MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021133750-A1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKA, DGKZ, DGKK | TSHR 2035/4885CYP3A4 4521/4885CYP2C19 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.